iShares US Medical Devices

Abbott's Diabetes Care Receives Over 700 Injury Reports

Abbott Launches New Ensure Max Protein Milk Drinks for Muscle Health

BD Medical Expands Hazardous Drug Contamination Detection in Collaboration with Chemoglo™

Medtronic's Deep Brain Stimulation System Label Expanded With FDA Approval

Edwards Lifesciences Reaffirms 2025 Sales Growth Guidance at 9%-10%

Medtronic Cochlear Implant Approved for Expanded Indications by FDA

Medtronic Gets FDA Approval for Hugo™ System in Urology Surgeries

Medtronic Uses Affera Ablation System for the First Time in Denmark

GE Healthcare and Mayo Clinic Launch Personalized Radiation Therapy Study

ResMed Inc. Reduced 3,189,451 CHESS Depositary Interests

GE HealthCare Signs Care Alliance Agreement with Rochester University

Shanghai Mayor Meets Boston Scientific CEO

Invesco Increases Boston Scientific Shares

Granite Investment Partners LLC Reduced Holdings in IDEXX Laboratories

1832 Asset Management Increased Holdings in Medtronic in Q2

Josh Jennings Maintains Hold Rating on Edwards Lifesciences with Caution

UBS Reiterates Buy Rating on Abbott Stock with a Price Target of $120

GE Healthcare Announces Pricing of $1.25 Billion Debt Offering

ResMed CFO Disposes of ResMed Common Stock

Intuitive Surgical VP Myriam Curet Sells Shares

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Tradr 2X Long ASTS Daily ETF

Able View Global

SNSE

VNDA

PRAX

Several healthcare and biotech stocks saw significant gains in after-hours trading on Thursday due to clinical updates, earnings results, and regulatory developments. Sensei Biotherapeutics surged 62.9%, Praxis Precision Medicines rose 24.8%, CooperCompanies climbed 13.0%, Vanda Pharmaceuticals gained 7.5%, Cue Biopharma increased 7.8%, and ResMed added 3.7%. Key drivers included positive clinical trial results, earnings reports, and regulatory decisions.

rttnews

Sensei Biotherapeutics

Vanda Pharma

Praxis Precision Medicines

Resmed

Cue BioPharma

Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

The FDA has linked at least seven deaths and hundreds of injuries to malfunctioning glucose monitors by Abbott Diabetes Care. The issue affects about 3 million FreeStyle Libre 3 and Libre 3 Plus devices, traced to one production line. Incorrect low glucose readings may lead to serious health risks. Abbott has reported 736 severe adverse events and is replacing affected sensors. The company has identified the issue's source and expects no major supply disruptions.

Thehill

Abbott Laboratories

Glucose monitor problems linked with deaths, injuries: FDA

Medtronic plc (MDT) has maintained its quarterly dividend of $0.71 per share, offering a forward yield of 2.78%. The company demonstrates strong financial health with consistent revenue growth, robust profitability metrics, and a solid balance sheet. While valuation metrics are near historical highs, analyst sentiment remains positive, suggesting market confidence in the medical device giant.

GuruFocus

Medtronic

 Medtronic (MDT) Maintains Quarterly Dividend of $0.71 Per Share

GEHC

Shares of GE HealthCare Technologies Inc. fell 1.28% to $82.52 on Thursday, underperforming the market. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. The stock ended a two-day winning streak and is 12.95% below its 52-week high of $94.80. Trading volume was 3.3 million, below the 50-day average of 3.7 million.

Dow Jones

GE HealthCare Tech

GE HealthCare Technologies Inc. Stock Falls Thursday, Underperforms Market

Medtronic plc has announced a cash dividend of $0.71 per ordinary share for the third quarter of fiscal year 2026, continuing its 48-year streak of annual dividend increases.

Reuters

Medtronic announces $0.71 cash dividend for third quarter of fiscal year 2026

The FDA has issued a warning regarding Abbott's FreeStyle Libre 3 glucose monitor sensors due to potential inaccuracies that could lead to serious health risks. This warning follows reports linking these devices to 736 serious injuries and seven fatalities. Despite these challenges, Abbott Laboratories maintains a robust financial profile and global market presence, characterized by strong profitability and efficient operations.

 FDA Issues Warning on Abbott (ABT) Glucose Monitors After Reported Deaths

Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing

marketscreener

Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing

Farrell Peter C Director of ResMed Inc [RMD] filed a Form 4 on December 4, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/3/25TransactionPlanned Sale(1) Shares2,000Price$251.47Value$502,940Ending Holdings: 68,773 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Dir Farrell Sells 2,000 ($502.9K) Of ResMed Inc [RMD]

Peter C. Farrell, Director of ResMed Inc., reported the sale of common shares. The filing is available via EDGAR, the SEC's system. This AI-generated news brief is informational and not financial advice.

ResMed Director Peter C. Farrell Reports Sale of Common Shares

Abbott has launched two new Ensure Max Protein shakes to support muscle health: Ensure Max Protein 42g for active adults and Ensure Max Protein 2 in 1 Muscle Support for older adults. The shakes aim to address muscle loss after age 40, with high protein content and essential nutrients. Former quarterback Matt Ryan is promoting the products to raise muscle health awareness. New data also highlights the benefits of protein in stabilizing glucose levels. The products are available exclusively at Walmart.

Press Releases

Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement

Edwards Lifesciences (EW) has updated its fiscal year 2025 financial outlook, projecting a revenue increase of 9% to 10% and showcasing strong financial health with robust margins. The company, a leader in medical devices specializing in structural heart disease treatments, provided this revised guidance at its annual investor conference. Despite positive analyst sentiment and strong financial indicators, a P/E ratio close to its 1-year high and recent insider selling activity suggest a mixed valuation picture.

Edwards Lifesciences

 Edwards Lifesciences (EW) Revises FY25 Revenue Projection Upward

Edwards Lifesciences Reiterates 2025 Guidance; 2026 Forecast Issued

Edwards Lifesciences Reiterates 2025 Guidance; 2026 Forecast Issued

Becton Dickinson and Co :BD AND CHEMOGLO™ COLLABORATE TO EXPAND HAZARDOUS DRUG CONTAMINATION TESTING FOR HEALTH CARE FACILITIES AND LABORATORIES

Becton Dickinson and

BD And Chemoglo Collaborate To Expand Hazardous Drug Contamination Testing For Health Care Facilities And Laboratories

Medtronic plc has received FDA approval for expanded labeling of its Deep Brain Stimulation system for treating dystonia, transitioning from HDE status to full effectiveness labeling. This approval enhances treatment pathways and access for patients and clinicians, covering chronic, intractable primary dystonia for adults and primary generalized dystonia for patients aged 12 or older.

Medtronic Wins FDA Approval for Expanded Deep Brain Stimulation Labeling for Dystonia

Edwards Lifesciences reaffirms strategy for sustainable, differentiated growth at annual investor conference

Edwards Lifesciences reaffirms strategy for sustainable, differentiated growth at annual investor conference